drugset
drugset / Trial / NCT06087978

Study of RPT193 in Healthy Adult Male Subjects

NCT06087978 ↗

Phase 1 Completed 7 enrolled RAPT Therapeutics, Inc.
NaSingle-groupOpen-labelBasic science

Summary

Phase 1, open-label, absorption, metabolism, excretion, and mass balance study.

Timeline

Start
2023-07-05
Primary completion
2023-10-12
Completion
2023-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject RPT193 Unknown 400 mg Oral

Indications

No indication recorded.